6BVB image
Deposition Date 2017-12-12
Release Date 2018-08-01
Last Version Date 2023-10-04
Entry Detail
PDB ID:
6BVB
Keywords:
Title:
Crystal structure of HIF-2alpha-pVHL-elongin B-elongin C
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.00 Å
R-Value Free:
0.23
R-Value Work:
0.19
R-Value Observed:
0.20
Space Group:
P 43 21 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Elongin-B
Gene (Uniprot):ELOB
Chain IDs:B
Chain Length:118
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Elongin-C
Gene (Uniprot):ELOC
Chain IDs:C
Chain Length:96
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Hypoxia-Inducible Factor 2 alpha
Chain IDs:D (auth: H)
Chain Length:19
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:von Hippel-Lindau disease tumor suppressor
Gene (Uniprot):VHL
Chain IDs:A (auth: V)
Chain Length:162
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation
HIF-2 alpha-pVHL complex reveals broad genotype-phenotype correlations in HIF-2 alpha-driven disease.
Nat Commun 9 3359 3359 (2018)
PMID: 30135421 DOI: 10.1038/s41467-018-05554-1

Abstact

It is definitively established that mutations in transcription factor HIF-2α are causative of both neuroendocrine tumors (class 1 disease) and polycythemia (class 2 disease). However, the molecular mechanism that underlies this emergent genotype-phenotype relationship has remained unclear. Here, we report the structure of HIF-2α peptide bound to pVHL-elongin B-elongin C (VBC) heterotrimeric complex, which shows topographical demarcation of class 1 and 2 mutations affecting residues predicted, and demonstrated via biophysical analyses, to differentially impact HIF-2α-pVHL interaction interface stability. Concordantly, biochemical experiments showed that class 1 mutations disrupt pVHL affinity to HIF-2α more adversely than class 2 mutations directly or indirectly via impeding PHD2-mediated hydroxylation. These findings suggest that neuroendocrine tumor pathogenesis requires a higher HIF-2α dose than polycythemia, which requires only a mild increase in HIF-2α activity. These biophysical data reveal a structural basis that underlies, and can be used to predict de novo, broad genotype-phenotype correlations in HIF-2α-driven disease.

Legend

Protein

Chemical

Disease

Primary Citation of related structures